Am Fam Physician. 2022;106(5):582-583
Author disclosure: No relevant financial relationships.
Vericiguat (Verquvo) is labeled for the treatment of adults with symptomatic chronic heart failure (HF) and an ejection fraction of less than 45%. It is used to reduce the composite risk of cardiovascular death and HF-related hospitalization following a previous hospitalization for HF or the need for outpatient intravenous diuretics.1 Vericiguat causes smooth muscle relaxation and vasodilation by stimulating soluble guanylate cyclase (which is decreased in HF), both independently and synergistically with nitric oxide, a unique mechanism.
Drug | Dosage | Dose form | Cost of full course* |
---|---|---|---|
Vericiguat (Verquvo) | Initial dosage of 2.5 mg once daily with food, then doubled every two weeks to reach target dosage of 10 mg daily, as tolerated | Tablets: 2.5mg; 5 mg; 10 mg | $640 |
Subscribe
From $165- Immediate, unlimited access to all AFP content
- More than 130 CME credits/year
- AAFP app access
- Print delivery available
Issue Access
$59.95- Immediate, unlimited access to this issue's content
- CME credits
- AAFP app access
- Print delivery available